Optimizing neoadjuvant treatment for HER2‑positive early breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

EUREKA is an open-label phase II adaptive neoadjuvant approach for patients with cT2–T3 N0–2 HER2‑positive breast cancer that uses a phosphoprotein assay (HARPS) to classify tumors as HARPS‑positive or HARPS‑negative. HARPS‑positive patients begin with three cycles of trastuzumab and pertuzumab and are monitored with ctDNA and breast MRI to decide whether to continue dual HER2 therapy or add a single-agent taxane for nonresponders before surgery. HARPS‑negative patients with detectable ctDNA receive a taxane/platinum plus trastuzumab and pertuzumab regimen and are followed for ctDNA clearance to guide additional cycles. Primary endpoints include pathologic complete response and three‑year invasive disease‑free survival, with correlative analyses of ctDNA dynamics and quality-of-life measures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion Criteria

  1. Tumor size greater than 2cm or lymph node positive by imaging or clinical exam (cT2-T3 N0-2)
  2. Tumors must be HER2 positive either by IHC (3+) or by IHC 2+ and FISH positive.
  3. Patient must have known estrogen receptor (ER) and progesterone receptor (PR) status locally determined prior to study entry
  4. Patient must have adequate tumor for HARPS testing.
  5. Patients must have ctDNA collection prior to treatment on trial.
  6. Patient must be able to do breast MRI as determined by the study
  7. Baseline LVEF \> 50% (Most recent within the last 5 years)
  8. No prior history of systemic treatment with anthracyclines-based chemotherapy.
  9. Adequate bone marrow function:

     * ANC ≥ 1500/uL
     * platelet count ≥ 100,000/uL
     * hemoglobin ≥ 9.0 g/dL
  10. Adequate hepatic function:

      * Total bilirubin ≤ 1.5 X ULN
      * AST (SGOT) ≤ 5 X ULN
      * ALT (SGPT) ≤ 5 X ULN
  11. Patients with biliary obstruction must have restored biliary flow by placement of an endoscopic common bile duct stent or a percutaneous drainage.
  12. Adequate renal function, Creatinine \< 1.5x institutional ULN or calculated creatinine clearance ≥ 50 mL/min as estimated using the Cockcroft-Gault formula.
  13. Ability to understand the nature of this study protocol and give written informed consent.
  14. Willingness and ability to comply with scheduled visits and treatment plans
  15. Prior cancers allowed if no evidence of disease in last 5 years. Prior history of ipsilateral invasive breast cancers are not allowed.

Exclusion Criteria:

1. Previous treatment with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy for invasive breast cancer. Exception: patients can start upto 1 cycle of HP prior to starting treatment on study.
2. cT4 and/or cN3 tumors
3. Evidence of metastatic disease by routine clinical assessment
4. Bilateral breast cancer
5. History of other malignancy within the last five years prior to first dose of study drug administration, except for curatively treated basal and squamous cell carcinoma of the skin and/or in situ cervical carcinoma
6. Left ventricular ejection fraction (LVEF) below 50% as determined by multiple-gated acquisition (MUGA) scan or echocardiography (ECHO)
7. No active liver disease.
8. Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study.
9. Pre-existing sensory neuropathy \> grade 1.
10. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months.
11. Serious non-healing wound, ulcer, or bone fracture
12. Patient with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C.
13. Patient who has a history of allergy or hypersensitivity to any of the study drugs.
14. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

Where it's running

• RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center
  Elizabeth, New Jersey, United States Recruiting
• RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
  Hamilton, New Jersey, United States Recruiting
• RWJBarnabas Health - Monmouth Medical Center
  Long Branch, New Jersey, United States Recruiting
• Rutgers Cancer Institute
  New Brunswick, New Jersey, United States Recruiting
• RWJBarnabas Health - Newark Beth Israel Medical Center
  Newark, New Jersey, United States Recruiting
• RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
  Somerville, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Mridula A George
• Email: mridula@cinj.rutgers.edu
• Phone: 732-235-9692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• Personalized brain-targeted TMS for smoking cessation

  A personalized brain-guided Transcranial Magnetic Stimulation (TMS) approach is tested against a standard TMS method to see if it better changes reward brain activity and reduces cravings and smoking in adults with tobacco use disorder.

  Recruiting Rutgers, The State University of New Jersey · Newark, New Jersey · NCT07812753

• Luminal Bladder Cancer: Testing Neoadjuvant Therapy vs Immediate Surgery in Luminal MIBC

  We’re testing whether moving straight to radical cystectomy is safe and effective for patients with luminal muscle-invasive bladder cancer compared to the standard neoadjuvant therapy followed by surgery.

  Recruiting Phase 2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07762586

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Sun Safe Together: a digital skin cancer prevention approach for teens and their parents

  A small, single-arm trial will test whether a 12-week digital program using teen MMS messages and a private Facebook group for parents can feasibly and acceptably improve sun safety among adolescents and their parents.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07681791

• Exercise and nasal insulin in Type 2 diabetes: does adding insulin spray help the brain more

  In older adults with Type 2 diabetes, researchers are testing whether combining regular exercise with an intranasal insulin spray improves brain blood flow and thinking abilities more than exercise with a placebo spray.

  Recruiting at 4 sites Phase 2/3 Rutgers, The State University of New Jersey · New Brunswick, New Jersey and 3 other locations · NCT07675499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.